“Prevention of Rupture with Enzastaurin in Vascular Ehlers-Danlos Syndrome”
Aytu BioPharma, Inc. will be sponsoring an upcoming clinical trial to evaluate the effectiveness of AR101 (enzastaurin) in preventing cardiac or arterial events in patients with:
Vascular Ehlers-Danlos Syndrome (VEDS)
Confirmed COL3A1 gene mutation
To find out more about this trial, simply fill out the form below.